Theradiag SA (Theradiag), formerly Biomedical Diagnostics SA is a biotechnology company that develops, manufactures, and markets in-vitro diagnostic products. The company provides product for the diagnostics of auto-immune diseases, allergies and infectious diseases. It develops product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. Theradiag provides tests using techniques and automatic devices and solutions for high-speed diagnostics. The company also offers multi-parametric monitoring system for treatment of autoimmune diseases by anti-TNF. It provides in-vitro diagnostic products in the fields of auto-immunity, allergies, infectious diseases and, more recently, oncology and molecular biology. The company offers services in the autoimmune disease diagnostic market. Theradiag is headquartered in Marne LA Vallee, France.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company TheraDiag SA - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Our reports have been used by over 10K customers, including:
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis - Pipeline Review, H2 2020, provides an overview of the Granulomatosis with Polyangiitis (Immunology) pipeline...
Vasculitis Disease - Global Clinical Trials Review, H2 2020 Summary clinical trial report, “Vasculitis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Vasculitis Clinical trials scenario.This report provides top line data relating to the clinical trials on Vasculitis. Report...
Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2020" provides an overview of Systemic Lupus Erythematosus Clinical trials scenario.This report provides top line data relating to the...
219 pages •
By Asia Market Information & Development Company
• Sep 2020
China’s demand for Monoclonal Antibody has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...